Drug · Small Molecule

Lomustine

CI-DRUG-00000347Explore in graph →NCIt C617 CHEMBL514 CIViC Approved

Regulatory

Approvals (5)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory3 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360414) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2019	Dec 31, 1976	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360422) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1976	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360430) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1976

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	17	7	28	86	5	CA, US	Aug 4, 1976	1994-07
Hodgkin Lymphoma	Approved	—	0	0	0	0	1	US	Aug 4, 1976	—
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	15	7	15	48	0	—	—	2001-04
Leukemia	Phase3	Phase 3	0	0	1	1	0	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Overexpression1
Bevacizumab + Lomustine

Clinical trials

Trials with this intervention (87)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 87 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05902169	Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD)	recruiting	Phase 3	560	CarTheraINDUSTRY	11	Sep 29, 2026	clinicaltrials
NCT06325683	Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: 7BRF0Z81KG
Aliases: 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, Ccnu, CCN-U, CCNU, Cecenu, Ceenu, CeeNU, Chloroethylcyclohexylnitrosourea, Chloroethylcyclo- Hexylnitrosourea, Citostal, Gleostine, GLEOSTINE, Lomeblastin, Lomustina, Lomustine, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, NSC-79037, Prava, RB-1509, WR-139017

Data updated 2 hours agoSource updated unknown

Identifiers

Codes (7)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01AD02	LOMUSTINE
DIN (Health Canada)	00360414	CEENU
DIN (Health Canada)